Shareholder Tools

Press Releases

Press Releases
Date Title and Summary View
Aug 27, 2014 WEST LAFAYETTE, Ind., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the Baird 2014 Health Care Conference on Wednesday, Sept. 3, at 2:20 p....
Aug 14, 2014 WEST LAFAYETTE, Ind., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the Company's scientific management team has been selected by the American Chemical Society as the recipient of the 2...
Aug 7, 2014 WEST LAFAYETTE, Ind., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that three posters will be presented by Endocyte scientists at the 248th American Chemical Society (ACS) National Meeting &...
Aug 5, 2014 WEST LAFAYETTE, Ind., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the Wedbush 2014 Life Sciences Management Access Conference on Tuesday, ...
Jul 29, 2014 - EC1456 Targeting Potent Tubulysin Payload to Advance in Phase 1 to Dose Similar to Vintafolide - - Conference Call Today at 4:30 p.m. EDT - WEST LAFAYETTE, Ind., July 29, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for p...
Jul 22, 2014 WEST LAFAYETTE, Ind., July 22, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT) announced today that the company will host a conference call on Tuesday, July 29, at 4:30 p.m. EDT to discuss its second quarter 2014 financial results and provide an operational update. Investors and the general public are invited to listen to a live webc...
Jun 17, 2014 WEST LAFAYETTE, Ind., June 17, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT) today announced that it has regained the worldwide rights to vintafolide in all indications from Merck, known as MSD outside the United States and Canada. Following a comprehensive portfolio assessment, Merck, through a subsidiary, has decided that it will no long...
May 19, 2014 WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. (NASDAQ:ECYT), today announced the withdrawal of conditional marketing authorization applications (CMA) from the European Medicines Agency (EMA) for vintafolid...
May 19, 2014 WEST LAFAYETTE, Ind., May 19, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that two poster presentations featuring Endocyte's SMDC E...
May 2, 2014 - Independent DSMB Recommends to Stop Phase 3 PROCEED Trial for Futility Following Interim Analysis - - Endocyte Initiates Phase 1 Trial of PSMA-Targeted Tubulysin SMDC (EC1169) in Prostate Cancer Following FDA Acceptance of IND - - Conference Call Today at 8:30 a.m. EDT - WEST LAFAYETTE, Ind., May 2, 2014 (GLOBE NEWSWIRE) ...
1
... NextLast
Add to Briefcase = add release to Briefcase